28515226|t|A neutralizing anti-G-CSFR antibody blocks G-CSF - induced neutrophilia without inducing neutropenia in nonhuman primates
28515226|a|Neutrophils are the most abundant WBCs and have an essential role in the clearance of pathogens. Tight regulation of neutrophil numbers and their recruitment to sites of inflammation is critical in maintaining a balanced immune response. In various inflammatory conditions, such as rheumatoid arthritis, vasculitis, cystic fibrosis, and inflammatory bowel disease, increased serum G-CSF correlates with neutrophilia and enhanced neutrophil infiltration into inflamed tissues. We describe a fully human therapeutic anti-G-CSFR antibody (CSL324) that is safe and well tolerated when administered via i.v. infusion to cynomolgus macaques. CSL324 was effective in controlling G-CSF -mediated neutrophilia when administered either before or after G-CSF. A single ascending-dose study showed CSL324 did not alter steady-state neutrophil numbers, even at doses sufficient to completely prevent G-CSF -mediated neutrophilia. Weekly infusions of CSL324 (â‰¤10 mg/kg) for 3 wk completely neutralized G-CSF -mediated pSTAT3 phosphorylation without neutropenia. Moreover, repeat dosing up to 100 mg/kg for 12 wk did not result in neutropenia at any point, including the 12-wk follow-up after the last infusion. In addition, CSL324 had no observable effect on basic neutrophil functions, such as phagocytosis and oxidative burst. These data suggest that targeting G-CSFR may provide a safe and effective means of controlling G-CSF -mediated neutrophilia as observed in various inflammatory diseases.
28515226	2	35	neutralizing anti-G-CSFR antibody	T116,T129	C0475463
28515226	36	42	blocks	T169	C0332206
28515226	43	48	G-CSF	T116,T129	C0079459
28515226	51	58	induced	T169	C0205263
28515226	59	71	neutrophilia	T047	C3665444
28515226	80	88	inducing	T169	C0205263
28515226	89	100	neutropenia	T047	C0027947
28515226	104	121	nonhuman primates	T015	C0237798
28515226	122	133	Neutrophils	T025	C0027950
28515226	147	155	abundant	T080	C2346714
28515226	156	160	WBCs	T025	C0023516
28515226	173	182	essential	T080	C0205224
28515226	195	204	clearance	T080	C0449297
28515226	208	217	pathogens	T001	C0450254
28515226	225	235	regulation	T038	C1327622
28515226	239	249	neutrophil	T025	C0027950
28515226	268	279	recruitment	T052	C2949735
28515226	292	304	inflammation	T046	C0021368
28515226	343	358	immune response	T042	C0301872
28515226	371	394	inflammatory conditions	UnknownType	C0544805
28515226	404	424	rheumatoid arthritis	T047	C0003873
28515226	426	436	vasculitis	T047	C0042384
28515226	438	453	cystic fibrosis	T047	C0010674
28515226	459	485	inflammatory bowel disease	T047	C0021390
28515226	487	496	increased	T081	C0205217
28515226	497	502	serum	T031	C0229671
28515226	503	508	G-CSF	T116,T129	C0079459
28515226	525	537	neutrophilia	T047	C3665444
28515226	542	550	enhanced	T052	C2349975
28515226	551	574	neutrophil infiltration	T039	C0751982
28515226	580	588	inflamed	T169	C0333348
28515226	589	596	tissues	T024	C0040300
28515226	618	623	human	T016	C0086418
28515226	624	635	therapeutic	T169	C0302350
28515226	636	656	anti-G-CSFR antibody	T116,T129	C0475463
28515226	658	664	CSL324	T116,T129	C0475463
28515226	703	715	administered	T169	C1521801
28515226	725	733	infusion	T061	C0574032
28515226	737	756	cynomolgus macaques	T015	C0024399
28515226	758	764	CSL324	T116,T129	C0475463
28515226	769	778	effective	T080	C1704419
28515226	794	799	G-CSF	T116,T129	C0079459
28515226	810	822	neutrophilia	T047	C3665444
28515226	828	840	administered	T169	C1521801
28515226	864	869	G-CSF	T116,T129	C0079459
28515226	880	894	ascending-dose	T033	C4297006
28515226	908	914	CSL324	T116,T129	C0475463
28515226	929	941	steady-state	T070	C0678587
28515226	942	960	neutrophil numbers	T059	C0200633
28515226	970	975	doses	T081	C0178602
28515226	976	986	sufficient	T080	C0205410
28515226	990	1000	completely	T080	C0205197
28515226	1009	1014	G-CSF	T116,T129	C0079459
28515226	1025	1037	neutrophilia	T047	C3665444
28515226	1046	1055	infusions	T061	C0574032
28515226	1059	1065	CSL324	T116,T129	C0475463
28515226	1087	1097	completely	T080	C0205197
28515226	1110	1115	G-CSF	T116,T129	C0079459
28515226	1126	1132	pSTAT3	T116,T123	C0253050
28515226	1133	1148	phosphorylation	T044	C0031715
28515226	1157	1168	neutropenia	T047	C0027947
28515226	1180	1186	repeat	T169	C0205341
28515226	1187	1193	dosing	T081	C0178602
28515226	1238	1249	neutropenia	T047	C0027947
28515226	1284	1293	follow-up	T058	C1522577
28515226	1309	1317	infusion	T061	C0574032
28515226	1332	1338	CSL324	T116,T129	C0475463
28515226	1357	1363	effect	T080	C1280500
28515226	1373	1383	neutrophil	T025	C0027950
28515226	1384	1393	functions	T169	C0542341
28515226	1403	1415	phagocytosis	T043	C0031308
28515226	1420	1435	oxidative burst	T043	C0085416
28515226	1443	1447	data	T078	C1511726
28515226	1448	1455	suggest	T078	C1705535
28515226	1461	1470	targeting	T169	C1521840
28515226	1471	1477	G-CSFR	T116,T192	C0080090
28515226	1501	1510	effective	T080	C1704419
28515226	1532	1537	G-CSF	T116,T129	C0079459
28515226	1548	1560	neutrophilia	T047	C3665444
28515226	1564	1572	observed	T169	C1441672
28515226	1584	1605	inflammatory diseases	T047	C1290884